Neurocrine's schizophrenia drug meets main goal in mid-stage study (updated)

Neurocrine Biosciences

28/08/2024 12:18

(Adds details throughout)
       Aug 28 (Reuters) - Neurocrine Biosciences  NBIX.O  said
on Wednesday its experimental drug to treat adults with
schizophrenia met the main goal in a mid-stage study. 
    A 20 milligram dose of the drug candidate, NBI-1117568,
helped significantly reduce severity of symptoms compared to
placebo in adult patients with the mental health condition, the
company said.
    The drug was generally safe and well tolerated at all doses
tested in the study, Neurocrine said, adding that it plans to
begin late-stage trials early next year.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Mariam.ESunny@thomsonreuters.com;))